How Palantir got into the NHS – podcast
A Guardian podcast episode features investigative journalist Lucas Amin discussing how the data analytics firm Palantir, sometimes labelled "the world's scariest company," secured a £330m contract with the NHS. Amin and colleague Peter Geoghegan investigated the relationship between the US tech giant and the UK's public health service, uncovering a story involving controversial politicians, paid political access and gaps in UK lobbying rules that allowed the company to build influence.
The episode, hosted by Nosheen Iqbal, also examines the practical fallout once Palantir's software was rolled out to NHS staff, asking whether it actually improved on the systems doctors and nurses previously used. The discussion draws on Amin and Geoghegan's investigative reporting to trace the political and regulatory pathways that enabled the contract, alongside frontline accounts of the software's real-world performance.
In short
- Palantir won a £330m NHS contract despite controversy over its reputation
- Investigation exposes political access and UK lobbying regulation loopholes
- Podcast examines whether the software improved on previous NHS systems
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Palantir is a leading data analytics firm with genuine technical capabilities addressing real challenges in NHS operations, and companies have the legitimate right to bid for government contracts and build relationships with decision-makers through legal means. Competitive procurement processes should evaluate proposals on technical merit and capability to solve operational problems; if regulatory frameworks permitted the company's approach, that reflects how modern business-government relationships function. The contract's success should be assessed on whether the software delivers practical improvements for patient care and NHS efficiency.
The case against
The investigation reveals regulatory gaps that allowed disproportionate influence through paid political access, raising genuine concerns about democratic accountability and procurement transparency in public spending. A company with a controversial global track record in data collection and government surveillance should face heightened scrutiny when handling sensitive NHS patient information, yet the process appears to have lacked sufficient public oversight and independent evaluation. The practical underperformance once deployed suggests that access and lobbying may have substituted for rigorous technical merit assessment, resulting in questionable value for a £330m public investment.
Explained simply
Palantir Technologies is an American company specialising in data analytics, which examines and organises large volumes of information. The firm secured a £330 million contract to supply software systems to the National Health Service, one of the largest such arrangements between the UK health service and a private technology firm.
The contract has attracted scrutiny over how it came to be agreed. Investigative reporting has traced the political relationships and lobbying activities that enabled the deal, revealing gaps in UK rules governing the disclosure of political influence. Questions have been raised about how decisions affecting NHS services came to be shaped by this process.
Since Palantir's software was deployed to NHS staff, debate has also focused on whether it actually improves on the systems doctors and nurses previously used. The practical performance of these tools matters, as they are now used regularly across the health service to manage patient information and support clinical work.
Art Business Celebrity Companies Culture Entertainment Markets Software Technology UK World